Furthermore, DFV890 is a novel NLRP3 inhibitor that can reduce the production of IL-1β/18; a Phase 1 multi-center clinical trial is ongoing in patients with very low-, low-, or intermediate-risk MDS (NCT05552469). This evidence concerns the gene NLRP3 and myelodysplastic syndrome.